<DOC>
	<DOCNO>NCT00042679</DOCNO>
	<brief_summary>The purpose study determine following : Whether LY900003 plus gemcitabine carboplatin make tumor small disappear , long . If treatment LY900003 plus gemcitabine carboplatin help live longer . The safety LY900003 plus gemcitabine carboplatin side effect might associate combination three drug . How LY900003 distribute broken body give carboplatin gemcitabine . Whether LY900003 affect way gemcitabine carboplatin distribute broken body .</brief_summary>
	<brief_title>A Phase 2 Trial Antisense Nucleotide PKC-Alpha ( LY900003 , ISIS 3521 ) Plus Gemcitabine Carboplatin Patients With Advanced , Previously Untreated Non-Small Cell Lung Cancer .</brief_title>
	<detailed_description>Definition : The phase 2 study provide important information regard effect LY900003 safety efficacy patient treat gemcitabine carboplatin . LY900003 give approximately 2 mg/kg/day first 14 day 21-day cycle . The dose schedule LY900003 administration base result prior study LY900003 currently use study LY900003 . Gemcitabine administer Days 1 8 1250 mg/m2 carboplatin give Day 1 AUC 5 .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Diagnosis NonSmallCell Lung Cancer . Stage IV Stage IIIB disease . ECOG Performance Status 0 1 . Adequate organ function One unidimensionally measurable lesion . Prior therapy NSCLC . Serious concomitant disorder . Untreated CNS metastasis . Uncontrolled , active infection . Previous LY900003/ISIS trial participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Non-Small-Cell Lung Cancer</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Carcinoma Squamous</keyword>
	<keyword>Adult Lung Cancer</keyword>
</DOC>